These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
289 related items for PubMed ID: 19016094
1. Reasons for cannabis use: patients with schizophrenia versus matched healthy controls. Schaub M, Fanghaenel K, Stohler R. Aust N Z J Psychiatry; 2008 Dec; 42(12):1060-5. PubMed ID: 19016094 [Abstract] [Full Text] [Related]
2. Anhedonia and social adaptation predict substance abuse evolution in dual diagnosis schizophrenia. Potvin S, Stip E, Lipp O, Roy MA, Demers MF, Bouchard RH, Gendron A. Am J Drug Alcohol Abuse; 2008 Dec; 34(1):75-82. PubMed ID: 18161645 [Abstract] [Full Text] [Related]
3. Implicit and explicit affective associations towards cannabis use in patients with recent-onset schizophrenia and healthy controls. Dekker N, Smeerdijk AM, Wiers RW, Duits JH, van Gelder G, Houben K, Schippers G, Linszen DH, de Haan L. Psychol Med; 2010 Aug; 40(8):1325-36. PubMed ID: 19917142 [Abstract] [Full Text] [Related]
5. [Schizophrenia and addiction: An evaluation of the self-medication hypothesis]. Potvin S, Stip E, Roy JY. Encephale; 2003 Aug; 29(3 Pt 1):193-203. PubMed ID: 12876543 [Abstract] [Full Text] [Related]
7. Differences of satisfaction with medication between patients with schizophrenia treated with typical antipsychotics and atypical antipsychotics. Watanabe A, Shibata I, Kato T. Psychiatry Clin Neurosci; 2004 Jun; 58(3):268-73. PubMed ID: 15149292 [Abstract] [Full Text] [Related]
9. Cannabis induces different cognitive changes in schizophrenic patients and in healthy controls. Jockers-Scherübl MC, Wolf T, Radzei N, Schlattmann P, Rentzsch J, Gómez-Carrillo de Castro A, Kühl KP. Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun 30; 31(5):1054-63. PubMed ID: 17482741 [Abstract] [Full Text] [Related]
10. Cannabis and schizophrenia: impact on onset, course, psychopathology and outcomes. Bersani G, Orlandi V, Kotzalidis GD, Pancheri P. Eur Arch Psychiatry Clin Neurosci; 2002 Apr 30; 252(2):86-92. PubMed ID: 12111342 [Abstract] [Full Text] [Related]
11. Cannabis using schizophrenia patients treated with atypical neuroleptics: do their symptoms differ from those of cannabis abstainers? Schaub M, Fanghaenel K, Senn C, Stohler R. Subst Use Misuse; 2008 Dec 30; 43(14):2045-52. PubMed ID: 19085437 [Abstract] [Full Text] [Related]
12. Relationship between cannabis and psychosis: Reasons for use and associated clinical variables. Mané A, Fernández-Expósito M, Bergé D, Gómez-Pérez L, Sabaté A, Toll A, Diaz L, Diez-Aja C, Perez V. Psychiatry Res; 2015 Sep 30; 229(1-2):70-4. PubMed ID: 26235479 [Abstract] [Full Text] [Related]
14. Reasons for cannabis use in men with and without psychosis. Green B, Kavanagh DJ, Young RM. Drug Alcohol Rev; 2004 Dec 30; 23(4):445-53. PubMed ID: 15763749 [Abstract] [Full Text] [Related]
17. Stabilization of the internal structure of persistent auditory verbal hallucinations in schizophrenia. Chang JS, Yi JS, Ahn YM, Kim JH, Kim YS. Aust N Z J Psychiatry; 2009 Mar 30; 43(3):244-51. PubMed ID: 19221913 [Abstract] [Full Text] [Related]
18. Antipsychotic drug treatment of schizophrenic patients with substance abuse disorders. San L, Arranz B, Martinez-Raga J. Eur Addict Res; 2007 Mar 30; 13(4):230-43. PubMed ID: 17851245 [Abstract] [Full Text] [Related]
19. [Schizophrenia and cannabis consumption: epidemiology and clinical symptoms]. Jockers-Scherübl MC. Prax Kinderpsychol Kinderpsychiatr; 2006 Mar 30; 55(7):533-43. PubMed ID: 17058779 [Abstract] [Full Text] [Related]